Obermatt

Medical Developments International

ASX:MVP · AU000000MVP2
PharmaceuticalsX-Small

360

79
Profit price1
Owner Earnings Yield55
Dividend Yield1
Price/Sales89
EV / Gross Profit79
Price/Book96
Return on Capital63
Cash Return on Capital58
Return on Equity57
EBIT Margin52
Gross Profitability87
Accruals51
Owner Earnings Margin51
Sales growth30
Profit Growth28
Long-Term EPS Growth89
Owner Earnings Growth30
Reinvestment71
Price momentum11
Debt load80
Refinancing55
Debt Payback100
Liquidity60
Analyst ratings100
Expectations trend50
Market mood45
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Medical Developments International clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryAustralia
IndustryPharmaceuticals
SizeX-Small
TypePublic Company
ExchangeASX
Founded2003
Employees80
ISINAU000000MVP2
Last UpdateApr 2, 2026
Index & Theme
Chronic DiseasesPain ManagementPulmonologyRespiratoryBiomedical EngineeringHealth CareManufacturingMedicalPharmaceutical

Description

Medical Developments International Limited is primarily engaged in the development and commercialization of innovative medical products, with a focus on pain management and respiratory solutions. The company is particularly noted for its flagship pro…

Analysis

Middle-of-the-road

Medical Developments International Limited sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

On valuation, the picture is expensive. The owner-earnings multiple stands at 126.3×; owner earnings: the cash an owner could take out each year.

Growth is moderate; the safety picture is sturdy. The company scores 12/20 on our value-creation score: creating some value. Analysts lean positive.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
56
2023202420252026

All-time high

56

Jun 2026

All-time low

13

Jan 2025

Average rank

30

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
89
44
66
13
Price/Earnings
1
75
75
36
Price/Book
96
81
73
23
Dividend Yield
1
1
1
1
Value (overall)
48
36
42
17

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Medical Developments International with its peers
Kyowa Hakko Kirin
TYO:4151
50
CountryJapan
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Il Dong Pharmaceutical
KSC:249420
53
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Nippon Shinyaku
TYO:4516
87
CountryJapan
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Shionogi
TYO:4507
70
CountryJapan
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Jeil Pharmaceutical
KSC:271980
70
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Hana Pharm
KSC:293480
88
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →